The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden

Background: Cure proportion represents the proportion of patients who experience the same mortality rate as the general population and can be estimated together with the survival of the proportion experiencing excess mortality (the uncured). The aim was to estimate the cure proportions and survival...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021, Vol.13 (10), p.2456
Main Authors: Eriksson, Hanna, Utjés, Deborah, Olofsson Bagge, Roger, Gillgren, Peter, Isaksson, Karolin, Lapins, Jan, Schultz, Inkeri Leonardsson, Lyth, Johan, Andersson, Therese M.-L.
Format: Article
Language:English
Subjects:
adjuvant dabrafenib
analysis
Biomarkers
Cancer and Oncology
Cancer och onkologi
Clinical Medicine
Cure proportions
european organization
III melanoma
ipilimumab
iv melanoma
Klinisk medicin
malignant-melanoma
median
Median survival times
Medical and Health Sciences
Medicin och hälsovetenskap
Melanoma
Metastasis
Mortality
nivolumab
Oncology
pooled
Skin cancer
stage II&#8211
Stage II–III melanoma
Surgery
Survival
Survival ratios
survival times
trametinib
Tumors
Uncured patients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Cure proportion represents the proportion of patients who experience the same mortality rate as the general population and can be estimated together with the survival of the proportion experiencing excess mortality (the uncured). The aim was to estimate the cure proportions and survival among uncured stage II–III cutaneous melanoma (CM) patients. Methods: 1- and 5-year relative survival ratios, cure proportions and the median survival times of uncured stage II–III CM patients in Sweden (n = 6466) were calculated based on data from the nationwide population-based Swedish Melanoma Register 2005–2013 with a follow-up through 2018. Results: Stages IIB and IIC showed significant differences in standardized cure proportions vs. stage IIA CM (0.80 (95% CI 0.77–0.83) stage IIA; 0.62 (95% CI 0.59–0.66) stage IIB; 0.42 (95% CI 0.37–0.46) for stage IIC). Significant differences in standardized cure proportions were found for stages IIIB and IIIC-D CM vs. stage IIIA (0.76 (95% CI 0.68–0.84) stage IIIA; 0.52 (95% CI 0.45–0.59) stage IIIB; 0.35 (95% CI 0.30–0.39) for stage IIIC–D). Conclusions: The results are emphasizing the poor prognosis with low proportions cured by surgery only for sub-groups of stage II–III CM, specifically within stages IIB–C CM.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13102456